Abraxis BioScience presents phase 3 trial data on metastatic malignant melanoma

[News]

Abraxis BioScience, Inc. presented trial design information from its ongoing phase 3 registration trial of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), in melanoma, an aggressive form of skin cancer that affects more than 68,000 people in the U.S. each year.

More... (http://www.news-medical.net/news/20100611/Abraxis-BioScience-presents-phase-3-trial-data-on-metastatic-malignant-melanoma.aspx)